ACEI

DRUG6 trials

Sponsors

St. Joseph's Hospital and Medical Center, Phoenix, Boehringer Ingelheim, Nanjing Children's Hospital, Uppsala University, Consorci Sanitari de Terrassa

Conditions

ACE InhibitorsARBAmantadineAntihistamine AllergyCOVIDCOVID19Henoch-Schoenlein Purpura NephritisHypertension

Phase 2

The Research of Standard Diagnosis and Treatment for HSPN With Mild Proteinuria in Children

Nanjing Children's HospitalHenoch-Schoenlein Purpura Nephritis

Start: 2015-08-31End: 2020-07-31Target: 100Updated: 2020-02-26

Phase 3

Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy

TerminatedNCT00318474

St. Joseph's Hospital and Medical Center, PhoenixIgA Nephropathy

Start: 2002-01-31End: 2010-03-31Updated: 2016-03-07

Phase 4

Randomized Evaluation of Beta Blocker and ACEI/ARB Treatment in MINOCA Patients - MINOCA-BAT

TerminatedNCT03686696

Uppsala UniversityMyocardial Infarction With Non-obstructive Coronary Arteries

Start: 2018-12-16End: 2023-08-22Updated: 2023-11-27

Unknown Phase

The Use of Angiotensin Receptor Blockers and the Risk of Cancer

CompletedNCT02215733

Boehringer IngelheimNeoplasm

Start: 2011-02-28Updated: 2014-08-13

Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection

RecruitingNCT04367883

Consorci Sanitari de TerrassaACE Inhibitors, Amantadine, Antihistamine Allergy +3

Start: 2020-03-01End: 2028-02-24Target: 3000Updated: 2026-03-25

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

CompletedNCT04467931

University of UtahCOVID, Hypertension

Start: 2020-01-19End: 2020-12-31Updated: 2021-04-28

Related Papers

Clinical study outcomes in IgA nephropathy: A systematic literature review and narrative synthesis.

2025-06-101 citations